Across TCGA pan-cancer cohorts, RAB1AP2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RAB1AP2’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RAB1AP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RAB1AP2 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

PRAD, BRCA, and LUSC are the cancer types where RAB1AP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAB1AP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.018	.014	2	view →
BRCA	All	II,III,IV	+0.014	.032	2	view →
LUSC	Male	All	−0.014	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RAB1AP2 RNA expression & survival · all RAB1AP2 data types